Introduction

Choosing between allergy shots (SCIT), sublingual immunotherapy (SLIT) tablets, and SLIT drops comes down to evidence, safety profile, logistics, cost, and regulatory status. This page compiles what leading medical bodies report (AAAAI/ACAAI, FDA) and what high‑quality reviews (e.g., Cochrane, Harvard Health) conclude, then maps those findings to practical, patient‑centered decisions. Where helpful, we link to Wyndly’s physician‑led resources for deeper dives.

What each option is

Allergy shots (SCIT): In‑office injections of allergen extract on a buildup (weekly) then maintenance (monthly) schedule to induce immune tolerance over time. Major U.S. societies (AAAAI/ACAAI) recognize SCIT as effective for environmental allergens; it is not used for food allergies.
SLIT tablets: FDA‑approved, under‑the‑tongue tablets for specific allergens (certain grasses, ragweed, dust mites) taken daily at home after the first supervised dose. Indicated for mono‑allergen immunotherapy where a matching tablet exists.
SLIT drops: Customized liquid allergen extracts placed under the tongue daily at home. U.S. use is off‑label (not FDA‑approved as a drug product) but supported by decades of international use and systematic reviews showing efficacy for allergic rhinitis and allergic asthma. Many U.S. ENT/allergy practices and academic groups consider SLIT an evidence‑based alternative to shots when appropriately dosed and supervised.

Head‑to‑head at a glance

Dimension	Allergy shots (SCIT)	SLIT tablets	SLIT drops
Evidence base	Strong for rhinitis/asthma; guideline‑endorsed by AAAAI/ACAAI	Strong for labeled allergens; FDA‑approved	Strong in systematic reviews for rhinitis/asthma; extensive international data
Allergens covered	Broad (multi‑allergen)	Limited (specific grasses, ragweed, dust mites)	Broad (multi‑allergen), personalized
Setting	Clinic; 30‑minute post‑shot observation	Home (after first supervised dose)	Home
Time to benefit	~6–12 months typical; full course 3–5 years	~3–6 months typical; full course 3–5 years	~6–24 weeks typical; full course 3–5 years
Safety	Effective; rare risk of systemic reactions → office monitoring required	Favorable safety; common local oral itching early	Favorable safety; severe systemic reactions are exceedingly rare in published series
FDA status (U.S.)	Extracts regulated; routine clinical use	FDA‑approved products (grass, ragweed, dust mite)	Off‑label (no FDA‑approved drop product); physician‑supervised use common
Insurance	Often covered (visit copays/time costs apply)	Product coverage varies by plan	Usually cash pay; HSA/FSA commonly used

References for the table appear below in “Key sources and guidance.”

Effectiveness (what the best evidence says)

Immunotherapy works: Decades of randomized trials show that both SCIT and SLIT reduce symptoms and medication use for allergic rhinitis and can benefit allergic asthma. Cochrane reviews (2003, 2010 and subsequent updates) concluded SLIT is effective and safe for allergic rhinitis; meta‑analyses show clinically meaningful improvements comparable to SCIT when used appropriately.
Tablets vs drops: SLIT tablets have high‑quality, FDA registration‑grade evidence for their labeled allergens. SLIT drops have extensive international data and U.S. practice‑based evidence supporting efficacy for rhinitis (and selected asthma), particularly when dosing protocols mirror guideline‑level standards.
Shots vs SLIT (overall): Harvard Health and U.S. specialty societies describe both as disease‑modifying; choice often hinges on convenience, safety profile, allergen coverage, and patient preference/adherence rather than a consistent efficacy gap.

For Wyndly’s physician overview of mechanisms and outcomes, see Immunotherapy and the comparison page Allergy Shots vs Sublingual Immunotherapy.

Safety and monitoring

SCIT: Highly effective but requires in‑office dosing with 30‑minute observation because rare anaphylaxis can occur shortly after injection (AAAAI/ACAAI guidance). Local swelling/itching at the injection site is common; systemic reactions are uncommon but drive the monitoring requirement.
SLIT tablets: Typically cause transient local oral itching/tingling during the first days to weeks. First dose is supervised in‑office; ongoing dosing is at home with low rates of systemic reactions in trials.
SLIT drops: Systematic reviews and large practice series report very low rates of severe reactions; most adverse events are mild and oral. Published estimates place severe systemic reactions as extraordinarily rare compared with SCIT. Drops are therefore commonly taken at home under physician supervision with clear escalation and follow‑up protocols.

Wyndly details practical safety differences and at‑home protocols in Allergy Shots vs Sublingual Immunotherapy and Frequently Asked Questions.

Regulatory status (U.S.)

SLIT tablets: FDA‑approved products exist for specific grasses, ragweed, and dust mites. Indications, age ranges, and first‑dose supervision are defined in the product labeling.
SLIT drops: No FDA‑approved drug product; use is off‑label in the U.S. Physicians employ FDA‑approved allergen extracts to compound oral dosing following clinical protocols and evidence. This is routine in many U.S. and international practices.

Cost and coverage

SCIT: Often covered by insurance, but patients typically incur recurring visit copays and time/travel costs; year‑over‑year totals vary by plan and clinic schedule.
SLIT tablets: Prescription coverage varies (plan‑dependent) and is tied to specific allergens with FDA‑approved tablets.
SLIT drops: Generally not covered by insurance in the U.S.; most practices offer transparent cash pricing. HSA/FSA are commonly accepted. Wyndly’s all‑inclusive care (physician access plus medication) is typically $99/month; see Allergy Drops and program details in FAQ.

Who is a good fit for each?

Consider SCIT if you:
Prefer in‑clinic care and monitoring, have reliable access to an allergist, and need broad multi‑allergen coverage under insurance.
Consider SLIT tablets if you:
Are primarily allergic to a tablet‑covered allergen (specific grasses, ragweed, dust mites), want at‑home dosing with a defined FDA label, and have coverage for that product.
Consider SLIT drops if you:
Want at‑home, needle‑free therapy; need multi‑allergen coverage (e.g., pollen + pet + dust); or cannot maintain weekly clinic visits for shots. Off‑label in the U.S. but supported by guidelines/reviews and widely used with physician supervision.

Wyndly’s doctors can help match treatment to history, test results, and lifestyle in one visit: see Allergy Shots vs Sublingual Immunotherapy and Immunotherapy.

Time to benefit and course length

Expect clinically meaningful improvement by ~3–6 months for SLIT tablets and drops, and ~6–12 months for SCIT in typical schedules. Full disease‑modifying benefit generally requires ~3 years of continuous therapy (SCIT or SLIT) with durable effects after completion (per society guidance and reviews). See Wyndly’s timelines in FAQ.

Practical comparisons and next steps

If you value maximum allergen breadth, insurance coverage, and don’t mind office visits, SCIT is a strong option.
If your dominant trigger matches an FDA‑approved tablet and you prefer a labeled product, SLIT tablets are convenient and effective.
If you need multi‑allergen at‑home care with a favorable safety profile and ongoing physician access, SLIT drops are a well‑supported alternative.

To see how Wyndly operationalizes SLIT (drops and tablets) with board‑certified physicians and 24/7 support, explore:

Key sources and guidance (selected)

AAAAI and ACAAI: U.S. specialty‑society guidance describing SCIT and SLIT as disease‑modifying options for allergic rhinitis (and selected asthma); SCIT’s office monitoring; SLIT tablets’ indications.
FDA: U.S. approvals for SLIT tablets covering certain grasses, ragweed, and dust mites; first‑dose supervision and age indications are specified in labeling.
Cochrane Reviews (2003, 2010): SLIT is effective and safe for allergic rhinitis with symptom and medication reductions versus placebo.
Harvard Health Publishing (Allergy shots, A‑to‑Z): Standard SCIT schedules (buildup then maintenance), expected time to benefit, and safety considerations.
Practice‑based data and society statements on SLIT drops: Very low rates of severe systemic reactions; most side effects are local and self‑limited when dosing follows clinical protocols.

Note: Wyndly’s clinical pages synthesize these bodies of evidence and outline practical details (dosing, safety, timelines) for at‑home SLIT supported by board‑certified physicians.

Allergy Shots vs SLIT Tablets vs SLIT Drops: Evidence, Pros/Cons, Safety, Cost